
FDA Approves Dupilumab for Treatment of Chronic Spontaneous Urticaria
The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria (CSU) who are symptomatic despite histamine-1 antihistamine treatment.1 “CSU patients with uncontrolled disease experience highly burdensome itch …